Recombinant Human FCGR2B protein, C-His Tag

Product Description

Cat

IMP-655

Official Symbol

FCGR2B

Product Overview

Recombinant Human FCGR2B protein(Accession # P31994)(Ala 46-Pro 217), fused to C-His Tag, was expressed in HEK293.

Expression System

HEK293

Species

Human

Tag

C-His Tag

Form

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Molecular Mass

The protein has a calculated MW of 20.4 kDa. The protein migrates as 25-33 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Protein length

Ala 46-Pro 217

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Reconstitution

It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

SDS-PAGE

Bioactivity-BLI 1

Loaded Human CD32b, His Tag (SPR & BLI verified) on HIS1K Biosensor, can bind Rituximab with an affinity constant of 4.30 μM as determined in BLI assay.

Bioactivity-BLI 2

Loaded Rituximab on FAB2G Biosensor, can bind Human CD32b, His Tag (SPR & BLI verified) with an affinity constant of 5.4 μM as determined in BLI assay.

Bioactivity-SPR 1

Immobilized Human CD32b, His Tag (SPR & BLI verified) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 10.1 μM as determined in a SPR assay.

Bioactivity-SPR 2

Immobilized Rituximab on CM5 Chip, can bind Human CD32b, His Tag (SPR & BLI verified) with an affinity constant of 5.5 μM as determined in a SPR assay.

Data Sheet MSDS

Datasheet MSDS

For research or industrial raw materials, not for personal medical use!

Online Inquiry